# OnCo record paper-haslam-jama-netw-open (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-haslam-jama-netw-open/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-haslam-jama-netw-open" ;
  schema:name "Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs"@en ;
  schema:description "Paper cited by two bottleneck pages and 32 idea pages, indexed on Europe PMC as PubMed record 31050774 and published in JAMA network open; the citing pages link this DOI, which is how the record was matched."@en ;
  schema:url <https://onco.cc/key-papers/paper-haslam-jama-netw-open/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamanetworkopen.2019.2535>, <https://pubmed.ncbi.nlm.nih.gov/31050774/>, <https://europepmc.org/article/MED/31050774> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1001/jamanetworkopen.2019.2535> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Haslam A, Prasad V" ;
  onco:related <https://onco.cc/bottlenecks/b-tme-immunosuppression/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/>, <https://onco.cc/ideas/idea-bio2-myeloid-engager-bispecific/>, <https://onco.cc/ideas/idea-bio2-complement-c5ar-blockade/>, <https://onco.cc/ideas/idea-nl-diet-covariates-io-trials/>, <https://onco.cc/ideas/idea-bio2-antigen-presentation-triage/>, <https://onco.cc/ideas/idea-bio2-cxcr2-neutrophil-blockade/>, <https://onco.cc/ideas/idea-bio2-lactate-acid-axis/>, <https://onco.cc/ideas/idea-bio2-engineered-bacteria-payloads/>, <https://onco.cc/ideas/idea-bio2-tertiary-lymphoid-induction/>, <https://onco.cc/ideas/idea-bio2-implantable-microdevice-screen/>, <https://onco.cc/ideas/idea-moon-cold-to-hot-programme/>, <https://onco.cc/ideas/idea-bio2-caf-subtype-assignment/>, <https://onco.cc/ideas/idea-bio2-histotripsy-immune-priming/>, <https://onco.cc/ideas/idea-bio2-oncolytic-regulated-il12/>, <https://onco.cc/ideas/idea-bio2-radiotherapy-sting-fractionation/>, <https://onco.cc/ideas/idea-bio2-io-biomarker-data-commons/>, <https://onco.cc/ideas/idea-bio2-antibiotic-stewardship-io/>, <https://onco.cc/ideas/idea-bio2-trem2-myeloid-reprogramming/>, <https://onco.cc/ideas/idea-bio2-til-reactivity-selection/>, <https://onco.cc/ideas/idea-bio2-fmt-plus-checkpoint-phase3/>, <https://onco.cc/ideas/idea-bio2-fibre-diet-io-trial/>, <https://onco.cc/ideas/idea-bio2-trained-immunity-priming/>, <https://onco.cc/ideas/idea-bio2-steroid-sparing-irae/>, <https://onco.cc/ideas/idea-bio2-intracavitary-immunotherapy/>, <https://onco.cc/ideas/idea-bio2-in-situ-vaccination-solid/>, <https://onco.cc/ideas/idea-bio2-spatial-signature-cdx/>, <https://onco.cc/ideas/idea-bio2-epigenetic-priming-cold-tumours/>, <https://onco.cc/ideas/idea-bio2-ctdna-six-week-io-switch/>, <https://onco.cc/ideas/idea-bio2-hypoxia-guided-adenosine/>, <https://onco.cc/ideas/idea-bio2-vascular-normalisation-window/>, <https://onco.cc/ideas/idea-bio2-neoadjuvant-biomarker-engine/>, <https://onco.cc/ideas/idea-bio2-tcr-repertoire-early-readout/> .